Bruna Pellini: Our New Manuscript Explores Sotorasib Plus T-DXd in KRAS G12C-Mutant NSCLC
Bruna Pellini: Our New Manuscript Explores Sotorasib Plus T-DXd in KRAS G12C-Mutant NSCLC / Andriy Marusyk, Bina Desai, Bruna Pellini, cancer, Denise Kalos, Bruna Pellini/LinkedIn Bruna Pellini: Our New Manuscript Explores Sotorasib Plus T-DXd in KRAS G12C-Mutant NSCLC Bruna Pellini,...
T-DXd Plus Sotorasib Shows Preclinical Promise in KRAS G12C-Mutant NSCLC
T-DXd Plus Sotorasib in KRAS G12C-Mutant NSCLC showed durable preclinical tumor regressions and highlighted HER2 testing gaps T-DXd Plus Sotorasib Shows Preclinical Promise in KRAS G12C-Mutant NSCLC KRAS G12C-mutant non-small cell lung cancer has become one of the clearest examples...
How Is Zoldonrasib Different From Other Therapies in KRAS G12D+ NSCLC?
Zoldonrasib (RMC-9805), a novel KRAS G12D RAS(ON) inhibitor, has demonstrated “promising activity” while being “very well tolerated” among patients with KRAS G12D-mutated non–small cell lung cancer (NSCLC), according to Jonathan Wesley Riess, MD, MS. In a conversation with CancerNetwork®, Riess...
Zoldonrasib Shows Promising Activity in KRAS G12D+ NSCLC
Zoldonrasib (RMC-9805), an investigational RAS(ON) inhibitor, exhibited promising antitumor activity among patients with previously treated KRAS G12D-mutated non–small cell lung cancer (NSCLC), according to a presentation on findings from the phase 1/1b RMC-9805-001 study (NCT06040541) at the 2026 American Association...
Evaluating the efficacy of G12C inhibitors in conjunction with Gamma Knife radiosurgery for KRAS-mutant non-small cell lung cancer brain metastases
AbstractPurpose KRAS G12C mutations occur in approximately 11% of non-small-cell lung cancer (NSCLC) patients and are associated with aggressive disease and poor prognosis. Although KRAS G12C-inhibitors are now approved, their impact on Gamma Knife radiosurgery (GKRS) outcomes remains unexplored. We...